Document is current
Any future updates will be listed below
-
Authors
Bon, Giulia https://orcid.org/0000-0002-5409-5864
Pizzuti, Laura
Laquintana, Valentina
Loria, Rossella
Porru, Manuela
Marchiò, Caterina
Krasniqi, Eriseld
Barba, Maddalena
Maugeri-Saccà, Marcello
Gamucci, Teresa
Berardi, Rossana
Livi, Lorenzo
Ficorella, Corrado
Natoli, Clara
Cortesi, Enrico
Generali, Daniele
La Verde, Nicla
Cassano, Alessandra
Bria, Emilio
Moscetti, Luca
Michelotti, Andrea
Adamo, Vincenzo
Zamagni, Claudio
Tonini, Giuseppe
Barchiesi, Giacomo
Mazzotta, Marco
Marinelli, Daniele
Tomao, Silverio
Marchetti, Paolo
Valerio, Maria Rosaria
Mirabelli, Rosanna
Russo, Antonio
Fabbri, Maria Agnese
D’Ostilio, Nicola
Veltri, Enzo
Corsi, Domenico
Garrone, Ornella
Paris, Ida
Sarobba, Giuseppina
Giotta, Francesco
Garufi, Carlo
Cazzaniga, Marina
Del Medico, Pietro
Roselli, Mario
Sanguineti, Giuseppe
Sperduti, Isabella
Sapino, Anna
De Maria, Ruggero
Leonetti, Carlo
Di Leo, Angelo
Ciliberto, Gennaro
Falcioni, Rita
Vici, Patrizia
-
Funding
Funding for this research was provided by:
Regina Elena Cancer Institute (Intramural Grant)
- License Information
-
More Information
Article History
Received: 4 September 2020
Accepted: 2 December 2020
First Online: 10 December 2020
Ethics approval and consent to participate
: The study was conducted in accordance with the Declaration of Helsinki. All patients provided written informed consent. The protocol was approved by institutional review boards at each study site.
: The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
: GB, RL, VL, EK, MB, MMS, RB, LL, CF, EC, DG, AC, VA, CZ, GT, GB, MM, DM, ST, PM, MRV, RM, MAF, NDO, EMV, DC, GS, FG, CG, PDM, MR, IS, AS, GC, RF, GS declare no conflicts of interest. LP received travel grants from Eisai, Roche, Pfizer, Novartis; speaker fees from Roche, Pfizer, Novartis, Gentili. CM has received personal consultancy fees from Bayer, Roche, Daiichi Sankyo, MSD. TG received travel grants from Eisai, Roche, Pfizer, Novartis; speaker fees/advisory boards from Roche, Pfizer, Novartis, Gentili, Lilly. CN received travel grants/personal fees from Pfizer, EISAI, Novartis, Merck Sharp &Dohme, AstraZeneca. NLV received personal fees from Eisai and Novartis; research funding from Eisai, travel grants from Pfizer, Roche, Gentili; consulting role from Celldex. Em.Br. is supported by the Italian Association for Cancer Research AIRC-IG 20583; he was supported by the International Association for Lung Cancer (IASLC), the LILT (LegaItaliana per la Lotta contro i Tumori) and Fondazione Cariverona; he received speakers’ and travels’ fee from MSD, Astra-Zeneca, Celgene, Pfizer, Helsinn, Eli-Lilly, BMS, Novartis and Roche; consultant’s fee from Roche, Pfizer; institutional research grants from Astra-Zeneca, Roche. Lu.Mos. received advisory board from Roche. An.Mic. received travel grants from Eisai, Celgene, Novartis, Ipsen; personal fees, advisory boards from EISAI, Novartis, Astra Zeneca, Teva, Pfizer, Celgene. A.R. received fees from Bristol, Pfizer, Bayer, Kyowa Kirin, Ambrosetti for advisory board activity; and speaker honorarium from Roche Diagnostics. OG received personal fees from Celgene, Novartis, Eisai; research funding from Eisai, consulting activities with Celgene, Eisai, Pfizer, Amgen. IP received personal fees/advisory boards from Roche, Pfizer, Novartis, Italfarmaco, Gentili, Pierre Fabre. MC received personal fees, advisory boards from Pierre Fabre, Astra Zeneca, Celgene, Eisai, Novartis, Lilly. RDM declares to be a scientific advisory board member at Exosomics SpA (Siena IT), Hibercell Inc. (New York, NY), Kiromic Inc. (Houston, TX) and at Exiris Inc. (Rome, IT). ADL received consulting fees from Novartis and Roche. PV received travel grants from Eisai, Roche, Pfizer, Novartis; speaker fees/advisory boards from Roche, Pfizer, Novartis, Gentili, Lilly.
